Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2022 Earnings Call Transcript

So it’s been very reassuring for us to continue to get that feedback from our prescribers that the main source of the business is from stimulants, especially with those who have experienced side effects and so forth. I’ll give you an example. I mean, about 15% are from stimulants who have major AEs, experiencing major side effects, another 15% who’ve tried stimulants, but just don’t work. I mean, what people forget also, for a lot of clients, the stimulants don’t work for everybody as well, not everybody responds to stimulant. And then there is a good portion, which is in the mid-teens, which is completely new patients and we would expect that obviously to grow over time. But in general, we’re pretty happy with the mix of patients and the source of business, especially early in the launch because that tells us that in the physicians’ minds, Qelbree is an option to all patients.

It’s not just an option as a second-line treatment and non-stimulant category. And as far as the GOCOVRI growth is concerned, most of the growth is coming because of the positioning, the message and really the effort that our sales force is putting out there. So we’ve been able to have a very clear positioning about the product and its uniqueness in the Parkinson’s area. It’s a very crowded space. Pretty much every product treats off episodes, but only GOCOVRI treat off episodes and deals with dyskinesia. And that is a clear message that is out in the marketplace that we are pushing and educating physicians around the fact that they can actually treat both, dyskinesia and of episodes with GOCOVRI, instead of all the other agents they use that not only treat off episodes but some of them actually like levodopa, carbidopa cause dyskinesia.

So clearly, GOCOVRI is that message is resonating, and that’s what’s resulting in what is a healthy growth on the prescription side.

Operator: I am seeing no further questions in the queue. I would now like to turn the conference back to Jack Khattar for closing remarks.

Jack Khattar: Thank you. In concluding our call this afternoon, I would like to emphasize that delivering strong growth in our business remains our top priority. As we mentioned earlier, excluding Trokendi XR, our business is expected to deliver growth rate of approximately 30% in revenues in 2023. I would like to thank all our employees for delivering another outstanding year with record revenues for Supernus and for positioning us well with solid momentum behind both Qelbree and GOCOVRI. We look forward to return to double-digit growth in revenues and delivering healthy operating margins that preceded our transition years. Thanks for joining us this afternoon, and we look forward to updating everyone on our next call.

Operator: This concludes today’s conference call. Thank you all for participating. You may now disconnect, and have a pleasant day.